Clinical experience with 12-month follow-up in patients after implantation of a novel long-tapered sirolimus 
drug-eluting stent

Jakub Podolec; Maciej Skubera; Łukasz Niewiara; Mateusz Podolec; Piotr Pieniążek; Krzysztof Bartuś; Krzysztof Żmudka; Jacek Legutko

doi:10.5114/aic.2019.83648

eISSN: 1897-4295
ISSN: 1734-9338

Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2019
vol. 15

Send email

Copy url:

abstract:

Original paper

Clinical experience with 12-month follow-up in patients after implantation of a novel long-tapered sirolimus drug-eluting stent

Jakub Podolec

,

Maciej Skubera

,

Łukasz Niewiara

,

Mateusz Podolec

,

Piotr Pieniążek

,

Krzysztof Bartuś

,

Krzysztof Żmudka

,

Jacek Legutko

Adv Interv Cardiol 2019; 15, 1 (55): 46–51

DOI: https://doi.org/10.5114/aic.2019.83648

Online publish date: 2019/03/15

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Podolec J, Skubera M, Niewiara Ł, et al. Clinical experience with 12-month follow-up in patients after implantation of a novel long-tapered sirolimus 
drug-eluting stent. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2019;15(1):46-51. doi:10.5114/aic.2019.83648.

APA

Podolec, J., Skubera, M., Niewiara, Ł., Podolec, M., Pieniążek, P.,  & Bartuś, K. et al. (2019). Clinical experience with 12-month follow-up in patients after implantation of a novel long-tapered sirolimus 
drug-eluting stent. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 15(1), 46-51. https://doi.org/10.5114/aic.2019.83648

Chicago

Podolec, Jakub, Maciej Skubera, Łukasz Niewiara, Mateusz Podolec, Piotr Pieniążek, Krzysztof Bartuś,  and Krzysztof Żmudka et al. 2019. "Clinical experience with 12-month follow-up in patients after implantation of a novel long-tapered sirolimus 
drug-eluting stent". Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej 15 (1): 46-51. doi:10.5114/aic.2019.83648.

Harvard

Podolec, J., Skubera, M., Niewiara, Ł., Podolec, M., Pieniążek, P., Bartuś, K., Żmudka, K.,  and Legutko, J. (2019). Clinical experience with 12-month follow-up in patients after implantation of a novel long-tapered sirolimus 
drug-eluting stent. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 15(1), pp.46-51. https://doi.org/10.5114/aic.2019.83648

MLA

Podolec, Jakub et al. "Clinical experience with 12-month follow-up in patients after implantation of a novel long-tapered sirolimus 
drug-eluting stent." Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, vol. 15, no. 1, 2019, pp. 46-51. doi:10.5114/aic.2019.83648.

Vancouver

Podolec J, Skubera M, Niewiara Ł, Podolec M, Pieniążek P, Bartuś K et al. Clinical experience with 12-month follow-up in patients after implantation of a novel long-tapered sirolimus 
drug-eluting stent. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2019;15(1):46-51. doi:10.5114/aic.2019.83648.

Introduction
Long lesions contribute to a significant number of percutaneous coronary interventions

Aim
To assess the efficacy and safety of a novel long-tapered drug-eluting stent (DES) at a 12-month follow-up (FU) in patients with long coronary atherosclerotic lesions

Material and methods
A prospective clinical cohort study was conducted in 32 patients who underwent percutaneous coronary intervention using a BioMime Morph tapered stent (Meril Life Sciences, India). The patients were followed for 3, 6, and 12 months. The safety endpoints were death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), and MACE and/or major bleeding.

Results
Mean lesion length was 48 mm (range: 35–70 mm) measured via quantitative coronary analysis (QCA). In most cases, the target lesion was located in the LAD (68.75%). A GuideLiner catheter (Vascular Solutions Inc., MN, USA) was used in 12.5% of procedures; buddy-wire technique in 9.4% of cases. Bifurcation lesions were treated in 40.6% of cases. Additional stent implantation was needed in 56% of the procedures (25% of cases due to proximal or distal dissection, or due to insufficient stent length in 31% of cases). On 12-month FU we observed 1 TLR (3.1%), 1 TVR (3.1%), and 1 non-cardiovascular death.

Conclusions
The long sirolimus-eluting stent with tapered structure was characterized by good deliverability in long coronary lesions, although in some cases “buddy wire” or extension microcatheter use was necessary. Follow-up at 3, 6, and 12 months showed no significant major adverse cardiovascular events related to the device.

keywords:

Clinical experience with 12-month follow-up in patients after implantation of a novel long-tapered sirolimus drug-eluting stent

Jakub Podolec , Maciej Skubera , Łukasz Niewiara , Mateusz Podolec , Piotr Pieniążek , Krzysztof Bartuś , Krzysztof Żmudka , Jacek Legutko

long-tapered stent, drug-eluting stent, long coronary lesion, coronary artery disease

Jakub Podolec

,

Maciej Skubera

,

Łukasz Niewiara

,

Mateusz Podolec

,

Piotr Pieniążek

,

Krzysztof Bartuś

,

Krzysztof Żmudka

,

Jacek Legutko